Observational studyGynecologic oncology2019
A combined score of clinical factors and serum proteins can predict time to recurrence in high grade serous ovarian cancer.
Observational study in Gynecologic oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 30 citations in OpenAlex.
- Identification of B cell antigens in solid cancer: initial insights and functional implications.Frontiers in immunology · 2025Review
- Secretome Analysis Using Affinity Proteomics and Immunoassays: A Focus on Tumor Biology.Molecular & cellular proteomics : MCP · 2024Review
- Review
- Prospects of liquid biopsy in the prognosis and clinical management of gastrointestinal cancers.Frontiers in molecular biosciences · 2024Review
- Polymeric immunoglobulin receptor (pIgR) in cancer.Journal of cancer research and clinical oncology · 2023Review
- Ovarian recurrence risk assessment using machine learning, clinical information, and serum protein levels to predict survival in high grade ovarian cancer.Scientific reports · 2023Article
- Mass Spectrometry-Based Proteomics of Epithelial Ovarian Cancers: A Clinical Perspective.Molecular & cellular proteomics : MCP · 2023Review
- Circulating proteins as predictive and prognostic biomarkers in breast cancer.Clinical proteomics · 2022Review
- Circulating Proteins Associated with Response and Resistance to Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.Cancers · 2022Article
- Slow Off-Rate Modified Aptamer (SOMAmer) Proteomic Analysis of Patient-Derived Malignant Glioma Identifies Distinct Cellular Proteomes.International journal of molecular sciences · 2021Article
- Advances in Aptamer-Based Biomarker Discovery.Frontiers in cell and developmental biology · 2021Review
- Factors affecting stability of plasma brain-derived neurotrophic factor.Scientific reports · 2020Article
- Multi-platform Affinity Proteomics Identify Proteins Linked to Metastasis and Immune Suppression in Ovarian Cancer Plasma.Frontiers in oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo investigate the utility of a combined panel of protein biomarkers and clinical factors to predict recurrence in serous ovarian cancer patients.
methodsWomen at Augusta University diagnosed with ovarian cancer were enrolled between 2005 and 2015 (n = 71). Blood was drawn at enrollment and follow-up visits. Patient serum collected at remission was analyzed using the SOMAscan array (n = 35) to measure levels of 1129 proteins. The best 26 proteins were confirmed using Luminex assays in the same 35 patients and in an additional 36 patients (n
resultsOf the 26 proteins, Brain Derived Neurotrophic Factor and Platelet Derived Growth Factor molecules were significant for predicting PFS on both univariate and multivariate analyses. All 26 proteins were combined with clinical factors using the elastic net algorithm. Ten components were determined to predict PFS (HR of 6.55, p-value 1.12 × 10
conclusionThe SHOC score can predict patient prognosis in remission. This tool will hopefully lead to early intervention and consolidation therapy strategies in remission patients destined to recur.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.